Literature DB >> 31120817

Use of Ventricular Assist Devices and Heart Transplantation for Advanced Heart Failure.

Leslie Miller1, Emma Birks2, Maya Guglin3, Harveen Lamba1, O H Frazier1.   

Abstract

There are only 2 treatments for the thousands of patients who progress to the most advanced form of heart failure despite the application of guideline-based medical therapy, use of ventricular assist devices and heart transplantation. There has been a great deal of progress in both of these therapies that have led to improved outcomes including significant improvement in survival and functional capacity. Heart transplantation offers the best short- and long-term survival for patients with end-stage heart failure, and the majority of these recipients achieve relatively limitless functional capacity for their age. However, the chronic shortage of available donors limits the number of recipients in the United States to an only 2500 patients/y or only a fraction of potential candidates. The significant improvement in outcomes now possible with durable ventricular assist devices has led to a significant increase in their use, which now exceeds the volume of heart transplants in the United States, with the greatest growth in use for those not considered to be candidates for heart transplantation, previously referred to as destination therapy. This article will review the substantial progress that has taken place for both of these life-saving treatment options, as well as the future directions.

Entities:  

Keywords:  cardiomyopathies; heart failure; mortality; survival; transplants

Mesh:

Year:  2019        PMID: 31120817     DOI: 10.1161/CIRCRESAHA.119.313574

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  11 in total

Review 1.  Bioengineering approaches to treat the failing heart: from cell biology to 3D printing.

Authors:  Moran Yadid; Hadas Oved; Eric Silberman; Tal Dvir
Journal:  Nat Rev Cardiol       Date:  2021-08-27       Impact factor: 32.419

2.  Comparison of the Hemocompatibility of an Axial and a Centrifugal Left Ventricular Assist Device in an In Vitro Test Circuit.

Authors:  Patrick Borchers; Patrick Winnersbach; Sandra Kraemer; Christian Beckers; Eva Miriam Buhl; Steffen Leonhardt; Rolf Rossaint; Marian Walter; Thomas Breuer; Christian Bleilevens
Journal:  J Clin Med       Date:  2022-06-15       Impact factor: 4.964

Review 3.  Targeting mitochondrial dysfunction with elamipretide.

Authors:  Chukwuemeka Obi; Alexander T Smith; Gregory J Hughes; Adedayo A Adeboye
Journal:  Heart Fail Rev       Date:  2022-01-17       Impact factor: 4.654

4.  Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.

Authors:  Kenneth M Borow; Alex Yaroshinsky; Barry Greenberg; Emerson C Perin
Journal:  Circ Res       Date:  2019-07-18       Impact factor: 17.367

Review 5.  Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist.

Authors:  Paolo Severino; Paul J Mather; Mariateresa Pucci; Andrea D'Amato; Marco Valerio Mariani; Fabio Infusino; Lucia Ilaria Birtolo; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Diagnostics (Basel)       Date:  2019-11-01

6.  Clinical potential of angiogenic therapy and cellular reprogramming.

Authors:  Christopher T Ryan; Vivek Patel; Todd K Rosengart
Journal:  JTCVS Open       Date:  2021-03-18

Review 7.  Cardiac Surgery in Advanced Heart Failure.

Authors:  Roger Hullin; Philippe Meyer; Patrick Yerly; Matthias Kirsch
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

8.  Transplantation of MITO cells, mitochondria activated cardiac progenitor cells, to the ischemic myocardium of mouse enhances the therapeutic effect.

Authors:  Daisuke Sasaki; Yuma Yamada; Jiro Abe; Atsuhito Takeda; Hideyoshi Harashima
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

Review 9.  Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells.

Authors:  Emma Claire James; Eva Tomaskovic-Crook; Jeremy Micah Crook
Journal:  Int J Mol Sci       Date:  2021-03-16       Impact factor: 5.923

10.  Phase I investigator-initiated study of the safety of MTC001 in patients with chronic ischemic heart failure.

Authors:  Takeshi Machino; Akira Sato; Nobuyuki Murakoshi; Masaki Ieda
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.